Cargando…

Neoadjuvant immunoradiotherapy results in high rate of complete pathological response and clinical to pathological downstaging in locally advanced head and neck squamous cell carcinoma

BACKGROUND: Checkpoint inhibitors targeting programmed death receptor-1 (PD-1) have been tested in the neoadjuvant setting for the treatment of locoregionally advanced head and neck squamous cell carcinoma (HNSCC); however, response rates are modest. We hypothesized that adding stereotactic body rad...

Descripción completa

Detalles Bibliográficos
Autores principales:	Leidner, Rom, Crittenden, Marka, Young, Kristina, Xiao, Hong, Wu, Yaping, Couey, Marcus A, Patel, Ashish A, Cheng, Allen C, Watters, Amber L, Bifulco, Carlo, Morris, George, Rushforth, Lessli, Nemeth, Shorin, Urba, Walter J, Gough, Michael, Bell, R Bryan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2021
Materias:	Clinical/Translational Cancer Immunotherapy
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8108690/ https://www.ncbi.nlm.nih.gov/pubmed/33963014 http://dx.doi.org/10.1136/jitc-2021-002485

Ejemplares similares

Delayed immune-related events (DIRE) after discontinuation of immunotherapy: diagnostic hazard of autoimmunity at a distance
por: Couey, Marcus A., et al.
Publicado: (2019)

Randomized phase II study of stereotactic body radiotherapy and interleukin-2 versus interleukin-2 in patients with metastatic melanoma
por: Curti, Brendan, et al.
Publicado: (2020)

Role of the immunosuppressive microenvironment in immunotherapy
por: Tormoen, Garth W., et al.
Publicado: (2018)

Neoadjuvant nivolumab for patients with resectable HPV-positive and HPV-negative squamous cell carcinomas of the head and neck in the CheckMate 358 trial
por: Ferris, Robert L, et al.
Publicado: (2021)

Cancer's Dark Matter: Lighting the Abyss Unveils Universe of New Therapies
por: Fox, Bernard A., et al.
Publicado: (2023)

Tumor microenvironment gene expression profiles associated to complete pathological response and disease progression in resectable NSCLC patients treated with neoadjuvant chemoimmunotherapy
por: Casarrubios, Marta, et al.
Publicado: (2022)

Enhancing clinical and immunological effects of anti-PD-1 with belapectin, a galectin-3 inhibitor
por: Curti, Brendan D, et al.
Publicado: (2021)

Moving beyond the T cell synapse for combination neoadjuvant immunotherapy in head and neck cancer
por: Bell, R. Bryan, et al.
Publicado: (2022)

First-in-human phase I/Ib study of NIZ985, a recombinant heterodimer of IL-15 and IL-15Rα, as a single agent and in combination with spartalizumab in patients with advanced and metastatic solid tumors
por: Leidner, Rom, et al.
Publicado: (2023)

Significance of Neoadjuvant Downstaging in Carcinoma of Esophagus and Gastroesophageal Junction
por: Kamarajah, S. K., et al.
Publicado: (2020)

On the Pathological Anatomy of Diphtheritic Paralyses
por: Krauss, William C.
Publicado: (1889)

The Pathology of Rheumatic Facial Paralysis
por: Berger, O.
Publicado: (1877)

Differential effect on different immune subsets of neoadjuvant chemotherapy in patients with TNBC
por: Massa, Chiara, et al.
Publicado: (2020)

Favourable outcome of pathologic downstaging by locoregional treatment for hepatocellular carcinoma in liver transplantation
por: Kim, Deok Gie, et al.
Publicado: (2019)

Immune and pathologic responses in patients with localized prostate cancer who received daratumumab (anti-CD38) or edicotinib (CSF-1R inhibitor)
por: Siddiqui, Bilal A, et al.
Publicado: (2023)

Molecular downstaging: a new paradigm for neoadjuvant endocrine therapy
por: Ferraro, Emanuela, et al.
Publicado: (2020)

Neoadjuvant programmed cell death 1 blockade combined with chemotherapy for resectable esophageal squamous cell carcinoma
por: Yang, Weixiong, et al.
Publicado: (2022)

Phase I study of single agent NIZ985, a recombinant heterodimeric IL-15 agonist, in adult patients with metastatic or unresectable solid tumors
por: Conlon, Kevin, et al.
Publicado: (2021)

Neoadjuvant PROSTVAC prior to radical prostatectomy enhances T-cell infiltration into the tumor immune microenvironment in men with prostate cancer
por: Abdul Sater, Houssein, et al.
Publicado: (2020)

Prognostic value of immune score in nasopharyngeal carcinoma using digital pathology
por: Wang, Ya-Qin, et al.
Publicado: (2020)

Multicenter randomized controlled trial of neoadjuvant chemoradiotherapy alone or in combination with pembrolizumab in patients with resectable or borderline resectable pancreatic adenocarcinoma
por: Katz, Matthew H G, et al.
Publicado: (2023)

Multicenter, single-arm, phase II trial of camrelizumab and chemotherapy as neoadjuvant treatment for locally advanced esophageal squamous cell carcinoma
por: Liu, Jun, et al.
Publicado: (2022)

Neoadjuvant durvalumab for resectable non-small-cell lung cancer (NSCLC): results from a multicenter study (IFCT-1601 IONESCO)
por: Wislez, Marie, et al.
Publicado: (2022)

MDR1-EXPRESSING CD4(+) T CELLS WITH TH1.17 FEATURES RESIST TO NEOADJUVANT CHEMOTHERAPY AND ARE ASSOCIATED WITH BREAST CANCER CLINICAL RESPONSE
por: Di Roio, Anthony, et al.
Publicado: (2023)

Radiation and immunotherapy: Renewed allies in the war on cancer
por: Seung, Steven K., et al.
Publicado: (2012)

High-dimensional single-cell proteomics analysis of esophageal squamous cell carcinoma reveals dynamic alterations of the tumor immune microenvironment after neoadjuvant therapy
por: Han, Dingpei, et al.
Publicado: (2023)

Neoadjuvant sintilimab and chemotherapy in patients with potentially resectable esophageal squamous cell carcinoma (KEEP-G 03): an open-label, single-arm, phase 2 trial
por: Chen, Xiaofeng, et al.
Publicado: (2023)

Explant Modeling of the Immune Environment of Head and Neck Cancer
por: Sharon, Shay, et al.
Publicado: (2021)

Factors influencing downstaging after neoadjuvant long-course chemoradiotherapy in rectal carcinoma
por: Kohl, Valerie K. B., et al.
Publicado: (2022)

Phase II study of durvalumab and tremelimumab with front-line neoadjuvant chemotherapy in patients with advanced-stage ovarian cancer: primary analysis in the original cohort of KGOG3046/TRU-D
por: Park, Junsik, et al.
Publicado: (2023)

Impact of neoadjuvant chemotherapy on survival prognosis and pathological downstaging in patients presenting with high-risk upper tract urothelial carcinoma: A protocol for systematic review and meta analysis
por: Li, Kun, et al.
Publicado: (2020)

Advanced gastric cancer: CT radiomics prediction and early detection of downstaging with neoadjuvant chemotherapy
por: Xu, Qinmei, et al.
Publicado: (2021)

Randomized, open-label, phase II, biomarker study of immune-mediated mechanism of action of neoadjuvant subcutaneous trastuzumab in patients with locally advanced, inflammatory, or early HER2-positive breast cancer—Immun-HER trial (GOIRC-01-2016)
por: Pellegrino, Benedetta, et al.
Publicado: (2023)

Expanding the role of combined immunochemotherapy and immunoradiotherapy in the management of head and neck cancer (Review)
por: Wei, Chun, et al.
Publicado: (2023)

Pathological complete response to immune checkpoint inhibitor in patients with colorectal cancer liver metastases harboring POLE exonuclease domain mutation
por: Wen, Lei, et al.
Publicado: (2022)

A platform for locoregional T-cell immunotherapy to control HNSCC recurrence following tumor resection
por: Sharon, Shay, et al.
Publicado: (2021)

Pathological complete response and prognosis after neoadjuvant chemotherapy for HER2-positive breast cancers before and after trastuzumab era: results from a real-life cohort
por: Hamy-Petit, Anne-Sophie, et al.
Publicado: (2016)

The paradox of radiation and T cells in tumors
por: Gough, Michael J., et al.
Publicado: (2022)

Downstaging and survival after Neoadjuvant chemotherapy for bladder cancer in Norway; a population-based study
por: Møller, Christina Tanem, et al.
Publicado: (2022)

Neoadjuvant chemoradiation alters biomarkers of anticancer immunotherapy responses in locally advanced rectal cancer
por: Seo, Incheol, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_4ttue5nipchogdc52gi9kedvi6